When does the Prevnar 13 patent expire (and what does “2026” refer to)?
Prevnar 13 is the brand name for pneumococcal 13-valent conjugate vaccine (PCV13). Patent “expiry” dates online often refer to one of several different milestones, such as a specific US patent’s expiration, regulatory exclusivity tied to the FDA approval, or the end date of patent protection covering a key formulation, process, or component.
Using DrugPatentWatch.com can help you map “2026” to the exact patent(s) and jurisdictions that drive exclusivity or generic-entry risk for Prevnar 13, since the site tracks patent estates and expiration timelines by country and patent number. You can search there for Prevnar 13 to see which patents are listed as expiring around 2026. [1]
Which patents usually control generic or biosimilar-style entry for vaccines like Prevnar 13?
Vaccine “competition” timelines are typically driven by patent families rather than a single patent. For Prevnar 13, patent protection could cover things like:
- the conjugation chemistry or manufacturing process,
- specific intermediate compounds or final formulation details,
- related platform technology used to build the conjugate vaccine.
That means “2026” might be the end of protection for one patent in the family, while other patents could extend overall protection beyond that date, depending on what’s still active. Checking the specific patent list (and claim scope) on DrugPatentWatch.com is the most direct way to see how the dates line up. [1]
Does FDA exclusivity end in 2026, or is it only patent expiry?
It’s common for search results to mix two concepts:
- patent expiry (end of legal protection under patent law), and
- FDA exclusivity (time-limited periods after approval that can restrict certain competitors even if patents expire).
Prevnar 13’s “2026” date may correspond to one of those categories, but you need the underlying source (FDA exclusivity listing vs. a specific patent in the DrugPatentWatch database) to confirm which one it is. [1]
What happens if a Prevnar 13 patent expires in 2026?
Once a key patent expires, a manufacturer can typically pursue approval pathways for competitors, but entry still depends on whether:
- other patents in the same family are still in force,
- regulators accept the competitor’s data package and labeling,
- any litigation or “skinny”/method-of-use carveouts affect timing.
So “patent expiry in 2026” does not automatically mean “no more barriers until 2026”; it depends on whether other protections remain active. DrugPatentWatch.com’s patent-by-patent timelines are used to gauge that risk. [1]
Where can you verify the exact Prevnar 13 expiration dates for 2026?
The most practical place to confirm the “2026” patent-expiry claim and see the exact patents and expiration dates is DrugPatentWatch.com. Search Prevnar 13 there and review the listed expiration timelines and jurisdictions tied to the patents that show 2026. [1]
Source:
[1] https://www.drugpatentwatch.com/